Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 24357690)

1.

It's time to bring dendritic cell therapy to type 1 diabetes.

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG.

Diabetes. 2014 Jan;63(1):20-30. doi: 10.2337/db13-0886. Review. No abstract available.

3.

Alternatives to islet transplantation: future cell sources of beta-like cells.

Bruns H, Schultze D, Schemmer P.

Clin Transplant. 2013 Jul-Aug;27 Suppl 25:30-3. doi: 10.1111/ctr.12153.

PMID:
23909499
4.

The potential role of dendritic cells in the therapy of Type 1 diabetes.

Lee CN, Lew AM, Wu L.

Immunotherapy. 2013 Jun;5(6):591-606. doi: 10.2217/imt.13.48. Review.

PMID:
23725283
5.

Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Hilkens CM, Isaacs JD.

Clin Exp Immunol. 2013 May;172(2):148-57. doi: 10.1111/cei.12038. Review.

6.

PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.

Graham JG, Zhang X, Goodman A, Pothoven K, Houlihan J, Wang S, Gower RM, Luo X, Shea LD.

Tissue Eng Part A. 2013 Jun;19(11-12):1465-75. doi: 10.1089/ten.TEA.2012.0643. Epub 2013 Apr 3.

7.

Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.

Barcala Tabarrozzi AE, Castro CN, Dewey RA, Sogayar MC, Labriola L, Perone MJ.

Clin Exp Immunol. 2013 Feb;171(2):135-46. doi: 10.1111/cei.12019. Review.

8.

Novel therapy for type 1 diabetes: autologous hematopoietic stem cell transplantation.

Li L, Gu W, Zhu D.

J Diabetes. 2012 Dec;4(4):332-7. doi: 10.1111/1753-0407.12002. Review.

PMID:
23190701
9.

Dendritic cell therapy for Type 1 diabetes suppression.

Giannoukakis N, Trucco M.

Immunotherapy. 2012 Oct;4(10):1063-74. doi: 10.2217/imt.12.76. Review.

PMID:
23148758
10.

Tolerogenic dendritic cells impede priming of naïve CD8⁺ T cells and deplete memory CD8⁺ T cells.

Kleijwegt FS, Jansen DT, Teeler J, Joosten AM, Laban S, Nikolic T, Roep BO.

Eur J Immunol. 2013 Jan;43(1):85-92. doi: 10.1002/eji.201242879. Epub 2012 Nov 12.

PMID:
23042025
11.

A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus.

Giannoukakis N, Trucco M.

Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):279-87. doi: 10.1097/MED.0b013e328355461b. Review.

PMID:
22760513
12.

It's time to halt the unacceptable toll of diabetes.

Dentzer S.

Health Aff (Millwood). 2012 Jan;31(1):6-7. doi: 10.1377/hlthaff.2011.1349. No abstract available.

13.

It's time to mow the GRAS in type 1 diabetes.

Schatz DA, Levine SR, Atkinson MA.

Diabetes. 2011 Nov;60(11):2669-71. doi: 10.2337/db11-1158. No abstract available.

14.

Immunotherapy-based strategies for the treatment of autoimmune diabetes: searching for the cure.

Phillips BE, Trucco M.

Curr Pharm Des. 2011;17(29):3217-23. Review.

PMID:
21864264
15.

Dendritic cells expressing BTLA induces CD8+ T cell tolerance and attenuates the severity of diabetes.

Li S, Zhang M, Xiang F, Zhao J, Jiang C, Zhu J.

Vaccine. 2011 Oct 13;29(44):7747-51. doi: 10.1016/j.vaccine.2011.07.125. Epub 2011 Aug 7.

PMID:
21827810
16.

Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.

Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M.

Diabetes Care. 2011 Sep;34(9):2026-32. doi: 10.2337/dc11-0472. Epub 2011 Jun 16.

17.
18.

[Dendritic cells: a new horizon in cell therapy for inflammatory bowel disease?].

Ricart E, Panés J, Benítez-Ribas D.

Gastroenterol Hepatol. 2011 Feb;34(2):100-6. doi: 10.1016/j.gastrohep.2010.10.011. Epub 2011 Feb 17. Spanish.

PMID:
21333391
19.
20.

Therapeutic induction of tolerance by IL-10-differentiated dendritic cells in a mouse model of house dust mite-asthma.

Lu M, Dawicki W, Zhang X, Huang H, Nayyar A, Gordon JR.

Allergy. 2011 May;66(5):612-20. doi: 10.1111/j.1398-9995.2010.02526.x. Epub 2011 Jan 17.

PMID:
21241316
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk